ES2059826T3 - Utilizacion de quimotripsina para inactivar el activador de precalicreina en productos sanguineos derivados de plasma humano o animal. - Google Patents
Utilizacion de quimotripsina para inactivar el activador de precalicreina en productos sanguineos derivados de plasma humano o animal.Info
- Publication number
- ES2059826T3 ES2059826T3 ES89890044T ES89890044T ES2059826T3 ES 2059826 T3 ES2059826 T3 ES 2059826T3 ES 89890044 T ES89890044 T ES 89890044T ES 89890044 T ES89890044 T ES 89890044T ES 2059826 T3 ES2059826 T3 ES 2059826T3
- Authority
- ES
- Spain
- Prior art keywords
- blood products
- chymotripsine
- calicreine
- inactivate
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
PARA EVITAR EL RIESGO DE REACCIONES SECUNDARIAS NO DESEADAS DE PRODUCTOS SANGUINEOS, EN ESPECIAL DE PREPARADOS DE ALBUMINA E INMUNOGLOBULINA G, SE FABRICAN ESTOS A PARTIR DE PLASMA APLICANDO QUIMIOTRIPSINA PARA DEJAR SIN EFECTIVIDAD ALGUNA EL ACTIVADOR DE PRECALICREINA, OBTENIENDOSE ESTAS PREPARACIONES MEDIANTE ENRIQUECIMIENTO FRACCIONADO DE PLASMAPROTEINAS, CON LA CONDICION DE QUE, EN CUALQUIER NIVEL DEL PROCESO DE FRACCIONAMIENTO, SE AÑADA UNA SOLUCION DE QUIMIOTRIPSINA, SEPARANDO LA QUIMIOTRIPSINA INMOVILIZADA ANTES DE TERMINAR LAS PREPARACIONES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0049488A AT391810B (de) | 1988-02-26 | 1988-02-26 | Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2059826T3 true ES2059826T3 (es) | 1994-11-16 |
Family
ID=3492093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES89890044T Expired - Lifetime ES2059826T3 (es) | 1988-02-26 | 1989-02-20 | Utilizacion de quimotripsina para inactivar el activador de precalicreina en productos sanguineos derivados de plasma humano o animal. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5094949A (es) |
| EP (1) | EP0330647B1 (es) |
| JP (1) | JPH07116052B2 (es) |
| AT (2) | AT391810B (es) |
| CA (1) | CA1338499C (es) |
| DE (1) | DE58905495D1 (es) |
| DK (1) | DK90589A (es) |
| ES (1) | ES2059826T3 (es) |
| FI (1) | FI93696C (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT391810B (de) * | 1988-02-26 | 1990-12-10 | Immuno Ag | Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators |
| MXPA05005328A (es) * | 2002-11-25 | 2005-08-16 | Octapharma Ag | Fraccion de albumina derivada de plasma con precalicreina empobrecida. |
| ES2221817B1 (es) * | 2004-07-26 | 2005-10-01 | Probitas Pharma, S.A. | "soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas". |
| FR2895263B1 (fr) | 2005-12-26 | 2008-05-30 | Lab Francais Du Fractionnement | Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1390541A (en) * | 1971-04-14 | 1975-04-16 | Otsuka Kagaku Yakuhin | Anti-inflammatory compositions |
| DE2835843A1 (de) * | 1978-08-16 | 1980-02-28 | Blutspendedienst Dt Rote Kreuz | Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten gammaglobulinloesung |
| US4272521A (en) * | 1979-07-16 | 1981-06-09 | Cutter Laboratories, Inc. | Purified immune serum globulin |
| US4251510A (en) * | 1979-08-15 | 1981-02-17 | Cutter Laboratories, Inc. | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
| CH664496A5 (de) * | 1982-05-31 | 1988-03-15 | Mochida Pharm Co Ltd | Material zur entfernung von immunkomplexen aus dem blut oder aus plasma. |
| AT383739B (de) * | 1983-03-16 | 1987-08-10 | Immuno Ag | Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen in immunglobulinhaeltigen blutfraktionen |
| AT376367B (de) * | 1983-03-16 | 1984-11-12 | Immuno Ag | Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten |
| AT390560B (de) * | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| AT391810B (de) * | 1988-02-26 | 1990-12-10 | Immuno Ag | Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators |
-
1988
- 1988-02-26 AT AT0049488A patent/AT391810B/de not_active IP Right Cessation
-
1989
- 1989-02-20 DE DE89890044T patent/DE58905495D1/de not_active Expired - Fee Related
- 1989-02-20 EP EP89890044A patent/EP0330647B1/de not_active Expired - Lifetime
- 1989-02-20 ES ES89890044T patent/ES2059826T3/es not_active Expired - Lifetime
- 1989-02-20 AT AT89890044T patent/ATE94071T1/de not_active IP Right Cessation
- 1989-02-22 CA CA000591730A patent/CA1338499C/en not_active Expired - Fee Related
- 1989-02-23 JP JP1045037A patent/JPH07116052B2/ja not_active Expired - Lifetime
- 1989-02-24 US US07/315,163 patent/US5094949A/en not_active Expired - Fee Related
- 1989-02-24 DK DK090589A patent/DK90589A/da unknown
- 1989-02-24 FI FI890907A patent/FI93696C/fi not_active IP Right Cessation
-
1991
- 1991-10-15 US US07/775,587 patent/US5324628A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0330647A2 (de) | 1989-08-30 |
| FI93696C (fi) | 1995-05-26 |
| JPH07116052B2 (ja) | 1995-12-13 |
| EP0330647B1 (de) | 1993-09-08 |
| DK90589A (da) | 1989-08-27 |
| JPH01261332A (ja) | 1989-10-18 |
| CA1338499C (en) | 1996-07-30 |
| ATA49488A (de) | 1990-06-15 |
| US5094949A (en) | 1992-03-10 |
| AT391810B (de) | 1990-12-10 |
| FI890907A (fi) | 1989-08-27 |
| US5324628A (en) | 1994-06-28 |
| ATE94071T1 (de) | 1993-09-15 |
| DK90589D0 (da) | 1989-02-24 |
| FI890907A0 (fi) | 1989-02-24 |
| EP0330647A3 (en) | 1990-05-09 |
| DE58905495D1 (de) | 1993-10-14 |
| FI93696B (fi) | 1995-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4632980B1 (es) | ||
| ES2032276T3 (es) | Metodo para el tratamiento de plasma y productos derivados del mismo. | |
| NO944997L (no) | Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte | |
| FI863703A (fi) | Glykocidderivat. | |
| DE69008664D1 (de) | Bestrahlung von bluterzeugnissen. | |
| ES2181725T3 (es) | Inhibidores de hiv proteasa. | |
| DE3587741D1 (de) | Behandlung von Hautkrankheiten. | |
| DE3854741D1 (de) | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. | |
| ATE116848T1 (de) | Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris. | |
| AR240403A1 (es) | Procedimiento para la esterilizacion de articulos utilizando vapor de peroxido de hidrogeno | |
| ATE165345T1 (de) | Sulfonsaeurederivate zur behandlung von viruserkrankungen | |
| ES524992A0 (es) | Procedimiento para higienizar o pasterizar fribrinogeno humano | |
| DE69106493D1 (de) | Sulfonische Stilbenderivate zur Behandlung von Viruserkrankungen. | |
| ATE69953T1 (de) | Verwendung von polysulfatierten heparinen. | |
| DE58906239D1 (de) | Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn. | |
| ES2059826T3 (es) | Utilizacion de quimotripsina para inactivar el activador de precalicreina en productos sanguineos derivados de plasma humano o animal. | |
| ATE135914T1 (de) | Aica riboside zur prophylaktischen behandlung von krankheiten mit einer verminderten durchblutung. | |
| DE3670956D1 (de) | Behandlung von fluessigkeiten. | |
| DK137589D0 (da) | Salicylsyreholdigt middel til behandling af hudsygdomme | |
| EA199700241A1 (ru) | Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран | |
| ES2034953T3 (es) | Un procedimiento para la preparacion de una tiazolona. | |
| ES2066753T3 (es) | Uso de un preparado, que contiene inmunoglobulina, para la profilaxis y la terapia del sida, en personas. | |
| SE8102161L (sv) | "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra | |
| DE3373978D1 (en) | Composition for the care or treatment of the human skin | |
| ES2026485T3 (es) | Esteres de salsalato con guayacol para tratar bronconeumopatias flogisticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 330647 Country of ref document: ES |